CRP and spondyloarthropathy: To be eligible to receive treatment with an anti-TNF in Europe, Assessment of SpondyloArthritis international Society (ASAS) treatment recommendations state that nr-axSpA patients must have either a positive CRP assessment (elevated CRP greater than the upper limit of normal (ULN)) or a positive MRI showing inflammation of the sacroiliac joints, in addition to meeting criteria for high disease activity [15, 16].